Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-08-17 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
第二届监事会第十次会议决议公告
Regulatory Filings Classification · 90% confidence The document is a formal announcement from the Supervisory Board of Shanghai Medicilon Inc. regarding the resolutions passed at their 10th meeting of the 2nd Supervisory Board. It specifically mentions the review and approval of the company's 2020 semi-annual report and a special report on the use of raised funds. The document states that the Supervisory Board confirms the accuracy and completeness of the semi-annual report but does not contain the report itself. It also references that the special report is published on the Shanghai Stock Exchange website. The document is relatively short (955 characters) and serves as an official announcement of meeting resolutions and approvals rather than the full semi-annual report. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Report Publication Announcement (RPA) because it contains substantive content about the meeting resolutions and legal assurances, not just a notice of report publication.
2020-08-17 Chinese
独立董事关于第二届董事会第十一次会议相关事项的独立意见
Regulatory Filings
2020-08-17 Chinese
2019年年度股东大会的法律意见书
Regulatory Filings
2020-05-18 Chinese
2019年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2019 Annual General Meeting (AGM) of Shanghai Medicilon Inc. It includes information about the meeting date, attendance, voting results on various proposals including the 2019 annual report, profit distribution, appointment of auditors, and amendments to company rules. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. It fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a brief report publication announcement or a full annual report, but a detailed voting result announcement from the AGM.
2020-05-18 Chinese
广发证券关于上海美迪西生物医药股份有限公司2019年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2019年度持续督导跟踪报告" (2019 Annual Continuous Supervision Follow-up Report) issued by the sponsor (广发证券股份有限公司) for the company 上海美迪西生物医药股份有限公司. It references regulatory frameworks related to continuous supervision after IPO on the STAR Market (科创板). The content includes detailed descriptions of the sponsor's supervision activities, risk factors, financial data for 2019, compliance with fundraising usage, shareholding details of directors and senior management, and other governance and operational matters. It is not a full annual report (10-K) but a specific continuous supervision report required by Chinese securities regulations for listed companies post-IPO. It is not an announcement or a brief notice but a substantive report with detailed financial and operational information. This type of document corresponds to an Audit Report / Information (AR) category, as it is a standalone regulatory report related to ongoing sponsor supervision and compliance, not the full annual report itself. The document length (13,129 characters) and detailed content support this classification with high confidence. FY 2019
2020-05-08 Chinese
2019年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled '2019 年年度股东大会会议资料' which translates to '2019 Annual General Meeting (AGM) Meeting Materials'. It contains detailed agenda items, reports, and proposals to be discussed and voted on at the 2019 AGM of Shanghai Medicilon Inc. The content includes meeting instructions, agenda, board reports, supervisory board reports, financial reports, independent director reports, and other proposals related to the AGM. The document is comprehensive and clearly intended as materials for the AGM itself, not just an announcement or summary. It is not a full annual report (10-K) but rather the materials prepared for the AGM. Therefore, the correct classification is AGM Information (AGM-R).
2020-05-08 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.